| scholarly article | Q13442814 |
| P2093 | author name string | Jie Zhang | |
| Zhiyong Wang | |||
| Xuan Sun | |||
| Ran Tian | |||
| Fei Zhang | |||
| Wei Ji | |||
| Ruifang Niu | |||
| P2860 | cites work | WSTF promotes proliferation and invasion of lung cancer cells by inducing EMT via PI3K/Akt and IL-6/STAT3 signaling pathways | Q51622540 |
| Shp2 promotes metastasis of prostate cancer by attenuating the PAR3/PAR6/aPKC polarity protein complex and enhancing epithelial-to-mesenchymal transition | Q52660753 | ||
| Expression of interleukin-6 is associated with epithelial-mesenchymal transition and survival rates in gallbladder cancer | Q53649097 | ||
| Involvement of EphA2-mediated tyrosine phosphorylation of Shp2 in Shp2-regulated activation of extracellular signal-regulated kinase | Q54457318 | ||
| Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signaling. | Q54652087 | ||
| Cancer development, chemoresistance, epithelial to mesenchymal transition and stem cells: A snapshot of IL-6 mediated involvement. | Q38762062 | ||
| IL-6 Overexpression in ERG-Positive Prostate Cancer Is Mediated by Prostaglandin Receptor EP2. | Q38783383 | ||
| EGF augments TGFβ-induced epithelial-mesenchymal transition by promoting SHP2 binding to GAB1. | Q38836180 | ||
| IL-6 originated from breast cancer tissue-derived mesenchymal stromal cells may contribute to carcinogenesis | Q38907957 | ||
| Upregulation of Src homology phosphotyrosyl phosphatase 2 (Shp2) expression in oral cancer and knockdown of Shp2 expression inhibit tumor cell viability and invasion in vitro | Q39033270 | ||
| IL-6 negatively regulates osteoblast differentiation through the SHP2/MEK2 and SHP2/Akt2 pathways in vitro | Q39079705 | ||
| Atypical Protein Kinase C Phosphorylates Par6 and Facilitates Transforming Growth Factor β-Induced Epithelial-to-Mesenchymal Transition | Q39224377 | ||
| IL-6 Promotes Head and Neck Tumor Metastasis by Inducing Epithelial–Mesenchymal Transition via the JAK-STAT3-SNAIL Signaling Pathway | Q39462532 | ||
| Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. | Q39828317 | ||
| Inhibition of SHP2 leads to mesenchymal to epithelial transition in breast cancer cells | Q39990859 | ||
| Multiple requirements for SHPTP2 in epidermal growth factor-mediated cell cycle progression | Q40018398 | ||
| Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma | Q40180313 | ||
| SHP-2 promoting migration and metastasis of MCF-7 with loss of E-cadherin, dephosphorylation of FAK and secretion of MMP-9 induced by IL-1beta in vivo and in vitro. | Q40466832 | ||
| SHP2 and UGP2 are Biomarkers for Progression and Poor Prognosis of Gallbladder Cancer | Q40662726 | ||
| Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance | Q41299746 | ||
| IL-6 increases B-cell IgG production in a feed-forward proinflammatory mechanism to skew hematopoiesis and elevate myeloid production | Q42956804 | ||
| Gastric cancer development in mice lacking the SHP2 binding site on the IL-6 family co-receptor gp130. | Q44709460 | ||
| Transgenic Drosophila models of Noonan syndrome causing PTPN11 gain-of-function mutations | Q46884632 | ||
| Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1 | Q24321087 | ||
| Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras | Q24564495 | ||
| Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines | Q28139004 | ||
| Germ-line and somatic PTPN11 mutations in human disease | Q28264474 | ||
| Chemical Dissection of the Effects of Tyrosine Phosphorylation of SHP-2 | Q30924451 | ||
| Anxa2 plays a critical role in enhanced invasiveness of the multidrug resistant human breast cancer cells | Q33504768 | ||
| Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells | Q33588841 | ||
| Chronic inflammation and cytokines in the tumor microenvironment | Q33678275 | ||
| Src-homology 2 domain-containing tyrosine phosphatase 2 promotes oral cancer invasion and metastasis | Q33792502 | ||
| SHP2 positively regulates TGFβ1-induced epithelial-mesenchymal transition modulated by its novel interacting protein Hook1. | Q34634255 | ||
| Different associations of CD45 isoforms with STAT3, PKC and ERK regulate IL-6-induced proliferation in myeloma | Q35579670 | ||
| Protein Kinase A (PKA) Phosphorylation of Shp2 Protein Inhibits Its Phosphatase Activity and Modulates Ligand Specificity | Q35583091 | ||
| PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase | Q35616065 | ||
| Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma | Q35742500 | ||
| A study on the effect of IL-6 gene polymorphism on the prognosis of non-small-cell lung cancer | Q36111795 | ||
| IL-1β induces IL-6 production and increases invasiveness and estrogen-independent growth in a TG2-dependent manner in human breast cancer cells | Q36127389 | ||
| Src Homology 2 Protein Tyrosine Phosphatase (SHPTP2)/Src Homology 2 Phosphatase 2 (SHP2) Tyrosine Phosphatase Is a Positive Regulator of the Interleukin 5 Receptor Signal Transduction Pathways Leading to the Prolongation of Eosinophil Survival | Q36380535 | ||
| SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer | Q36428439 | ||
| Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies | Q36551546 | ||
| IL-6 promotes growth and epithelial-mesenchymal transition of CD133+ cells of non-small cell lung cancer | Q36916291 | ||
| The tyrosine phosphatase SHP2 regulates focal adhesion kinase to promote EGF-induced lamellipodia persistence and cell migration | Q36941420 | ||
| The tyrosine phosphatase Shp2 (PTPN11) in cancer. | Q37088972 | ||
| A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growth | Q37109741 | ||
| Hormonal-receptor positive breast cancer: IL-6 augments invasion and lymph node metastasis via stimulating cathepsin B expression | Q37117208 | ||
| RING1B contributes to Ewing sarcoma development by repressing the NaV1.6 sodium channel and the NF-κB pathway, independently of the fusion oncoprotein | Q37564718 | ||
| Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis | Q38231309 | ||
| Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop | Q38327185 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P577 | publication date | 2017-02-13 | |
| P1433 | published in | International Journal of Molecular Sciences | Q3153277 |
| P1476 | title | Shp2 Plays a Critical Role in IL-6-Induced EMT in Breast Cancer Cells | |
| P478 | volume | 18 |
| Q89554795 | A specific amino acid context in EGFR and HER2 phosphorylation sites enables selective binding to the active site of Src homology phosphatase 2 (SHP2) |
| Q92114791 | Interleukin 6-triggered ataxia-telangiectasia mutated kinase activation facilitates epithelial-to-mesenchymal transition in lung cancer by upregulating vimentin expression |
| Q99565940 | SHP2 promotes proliferation of breast cancer cells through regulating Cyclin D1 stability via the PI3K/AKT/GSK3β signaling pathway |
| Q39390630 | Targeting interlukin-6 to relieve immunosuppression in tumor microenvironment |
| Q58783029 | The tyrosine phosphatase SHP2 controls TGFβ-induced STAT3 signaling to regulate fibroblast activation and fibrosis |
Search more.